Browse News
Filter News
Found 314 articles
-
Immunotherapy Drugs Industry is Rapidly Growing with CAGR of 18.03%
3/22/2024
According to Vision Research Reports, the global immunotherapy drugs market size was valued at USD 239.21 billion in 2023 and it is projected to hit around USD 1,063.44 billion by 2032, growing at a CAGR of 18.03% from 2023 to 2032.
-
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
3/19/2024
Enliven Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses.
-
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
3/14/2024
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company’s first DDC to enter the clinic.
-
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
3/14/2024
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN) today reported financial results for the fourth quarter and full year ended December 31, 2023, provided updated guidance on parallel lead product candidates and highlighted pipeline progress.
-
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
3/7/2024
Celularity Inc., a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced that it will present in vivo data from its T-cell therapy platform at this year’s AACR Annual Meeting.
-
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/7/2024
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Despite its overall survival and disease progression benefits, the U.K.’s drug cost watchdog has declined to recommend AstraZeneca and Daiichi Sankyo’s Enhertu due to a lack of cost-effectiveness.
-
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
3/5/2024
Vincerx Pharma, Inc. announced it will present three posters at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, CA, from April 5 – 10, 2024.
-
Antibody-drug conjugates are a breakthrough in targeted cancer therapy and will continue to attract big pharma investment over the next few years, finds a new report from market intelligence firm Evaluate.
-
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Pancreatic Cancer
2/29/2024
SN Bioscience Co. Ltd. announced on Feb 27 that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101, a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model.
-
The cancer space has been aflutter with notable approvals so far this year, but there are several more candidates with significant data expected over the next four months. BioSpace takes a closer look.
-
With the investment in the plant, Daiichi Sankyo is looking to create new laboratories for its antibody-drug conjugates used to develop and manufacture therapies for breast, lung and stomach cancers.
-
The regulator’s approval means AstraZeneca’s Tagrisso can now be used in combination with chemotherapy for locally advanced or metastatic EGFR-mutated non-small cell lung cancer patients.
-
The companies’ Biologics License Application for antibody-drug conjugate datopotamab deruxtecan has been accepted by the FDA for locally advanced or metastatic nonsquamous non-small cell lung cancer.
-
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
2/19/2024
Daiichi Sankyo and AstraZeneca’s Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer who have received prior systemic therapy.
-
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
2/17/2024
AstraZeneca’s TAGRISSO® with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
-
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
2/15/2024
Lantern Pharma Inc. announced an important milestone in its antibody-drug conjugate program.
-
AstraZeneca Full year and Q4 2023 Financial Results
2/8/2024
Strong growth and pipeline momentum with three new medicines approved since the third quarter
-
Buoyed by its strong performance outside of the U.S. market, Daiichi Sankyo on Wednesday again raised its sales expectations for the blockbuster antibody-drug conjugate.
-
AstraZeneca, Daiichi’s Enhertu Given FDA Priority Review for Metastatic HER2 Positive Solid Tumors
1/30/2024
The FDA has granted Priority Review for AstraZeneca and Daiichi Sankyo’s supplemental BLA for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors.